Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), announced that Shacey Petrovic, president and chief operating officer (COO), will succeed Patrick Sullivan as Insulet’s CEO, effective Jan. 1, 2019. She will continue to serve as Insulet’s president.
 
Sullivan will retire from the board at year end and will remain available to the company in a consulting role through the end of 2019. Timothy J. Scannell, who has served as a member of Insulet’s board for the last four years, will become chairman on Jan. 1, 2019. Petrovic joins Insulet’s board, effective immediately.
 
Petrovic joined Insulet as chief commercial officer in February 2015, and has served as the company’s president and COO since October 2016. In her current role, Petrovic directs the company’s day-to-day operations, leads its global growth initiatives, and manages its innovation, regulatory and clinical efforts. Under her leadership, Insulet has implemented a new product development roadmap and delivered record-breaking commercial results.
 
“It has been a great privilege to lead Insulet over the past four years, and I am proud of what we have accomplished and how well-positioned Insulet is for continued success,” said Sullivan. “We have achieved a great deal and the company is on a very positive growth trajectory. We have deliberately and thoughtfully planned for this succession and I am confident it’s the right time to transition the company to its next generation of leadership. Shacey has made a tremendous impact since joining Insulet and her insights and experience will be instrumental to take the company forward as a global leader in diabetes.”

Shacey Petrovic has served as Insulet’s president and COO since October 2016. From February 2016 to October 2016, she served as executive vice president and president, Diabetes Products, and from February 2015 to February 2016, she served as chief commercial officer. From 2013 to 2015, Petrovic served as president and CEO of Clinical Innovations LLC, a developer and manufacturer of medical devices and diagnostics for women’s health. From 2000 to 2013, she served in a number of key roles at Hologic Inc. and Cytyc Corporation, which merged with Hologic in October 2007, including vice president and general manager of Hologic’s GYN Surgical Products division, as well as various sales and marketing leadership roles in the United States and Europe. Petrovic earned her bachelor of science degree in biology from the University of Wisconsin.
 
“Pat has done an outstanding job establishing Insulet’s leadership within the industry and positioning the company for continued growth," Petrovic said. "I have learned a tremendous amount from his mentorship and I appreciate his strong example of dedication, discipline and strategic vision. This is a time of incredible opportunity for Insulet, and I am focused on building on our significant momentum to drive growth and continued value creation. It will be a privilege to lead this company, and I look forward to working with the entire Insulet team to achieve our strategic and financial objectives while furthering our mission to improve the lives of people with diabetes.”

Scannell has served on Insulet’s Board of Directors since August 2014. Since August 2018, he has served as the president and COO at Stryker Corporation. From 2009 to August 2018, he served as a group president at Stryker and oversaw several of Stryker’s operating divisions, including Instruments, Medical, Endoscopy, Neurovascular, CMF, and Sustainability Solutions. From 1990 to 2009, Scannell served in various roles at Stryker, including a range of sales and marketing leadership roles, vice president and general manager of its Biotech division and president of its Spine business. Scannell earned his bachelor degree in business administration and his master's degree in business administration from the University of Notre Dame.
 
“The leadership succession plan announced today is the culmination of a thoughtful, robust process to ensure that Insulet is best positioned to continue delivering sustainable long-term value creation,” said Dr. Jessica Hopfield, lead independent director of Insulet’s Board of Directors. “Pat has done an outstanding job leading Insulet through a crucial period of innovation, global expansion, commercial success, and operational improvement. The board is grateful for his innumerable contributions and his continued leadership during the transition period. Shacey has intimate knowledge of Insulet, a track record of performance and value creation and two decades of experience in the medical device industry, which make her uniquely qualified to deliver on Insulet’s incredible potential. On behalf of the board, we look forward to seeing the company reach new levels of success under Shacey’s leadership.”
 
Insulet Corporation, headquartered in Massachusetts, is dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives.
 
On July 1, Insulet assumed direct operations of its Omnipod Insulin Management System product line in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as Insulet does in the United States and Canada.